Chroma, a startup building a new type of audiovisual entertainment for mobile devices, has been sold. The company, which had financial backing from Twitter and Medium co-founder Biz Stone as well ...

The combined company, which will pair Chroma’s epigenetic editing with Nvelop’s non-viral particles, has raised $75 million ...

In industry parlance, the deal joins a “delivery” company with a “cargo” company — fusing the two key pieces needed to build ...

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and rounded up a $75 million financing.

The merger of Nvelop Therapeutics and Chroma Medicine brings together a combination of epigenetic editing and in vivo ...

The new company has also raised $75 million that will support the development of epigenetic editing therapies for hepatitis B ...

Two Boston-area biotechs are shedding staff and merging together to form a new genetic medicines company. | Chroma Medicines ...

Chroma Medicine and Nvelop Therapeutics today announced their merger and subsequent launch of nChroma Bio ("nChroma" or "the company") to redefine the future of genetic medicines. nChroma brings ...